<prompt> What is true about HER2neu overexpression in Ca breastGood prognosisResponds well to taxanesResponds well to monoclonal antibodiesSeen only in breast cancer  <response>: . Tumour grade, growth factor and oncogene factors. ErbB2 -Her-2neu positive has got poor prognosis. ErbB1 with over expression of epidermal growth factor EGF, TGF alpha and cathepsin D has got poor prognosis. Progesterone receptor PR status study or Her 2 Neu receptor status or cErb B2 growth factor receptor study are other studies done at present to plan the therapy and assess the prognosis. TRANSTUZUMAB Herceptin- It is a monoclonal antibody that blocks HER-2neu receptors thereby preventing growth of cancer cells. It is a new drug. It is presently marketed as herceptin. It is c-ErbB2 growth factor receptor inhibitor. It is a newer biological agent. It has very little effect on HER-2neu negative cancers. It is useful only in HER-2neu positive cancers. It is currently approved by FDA for use only in metastatic disease. It is given as intravenous infusion. ref:SRB;s manual of surgery,ed 3,pg no 486 